Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Clinical Trial ID NCT00110188

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeting metabolic transformation for cancer therapy.	Nat Rev Cancer	2010	5.90
2	Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.	Curr Cancer Drug Targets	2009	1.66
3	Advancing precision medicine for prostate cancer through genomics.	J Clin Oncol	2013	1.16
4	Novel targeted therapeutics for metastatic castration-resistant prostate cancer.	Cancer Lett	2009	1.04
5	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.	Prostate Cancer Prostatic Dis	2011	0.93
6	Castration-resistant prostate cancer: targeted therapies and individualized treatment.	Oncologist	2011	0.85
7	Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.	Clin Genitourin Cancer	2012	0.82
8	Research in castration-resistant prostate cancer: what does the future hold?	Curr Oncol	2010	0.79
9	Future directions in castrate-resistant prostate cancer therapy.	Clin Genitourin Cancer	2010	0.79
10	Recent advances in prostate development and links to prostatic diseases.	Wiley Interdiscip Rev Syst Biol Med	2013	0.79
11	Ridaforolimus.	Drugs R D	2010	0.78